Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 12/20 | 0.47 |
| ▸ | OGA | O60502 | 1/20 | 0.41 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.40 |
| ▸ | CLK2 | P49760 | 1/20 | 0.39 |
| ▸ | CXCR3 | P49682 | 4/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20899409 | 1.00 | LRRK2 (0.47) | LRRK2OGAMAP3K12CLK2CXCR3 | |
| SCHEMBL23554662 | 1.00 | LRRK2 (0.47) | LRRK2OGAMAP3K12CLK2CXCR3 | |
| SCHEMBL20898520 | 0.90 | LRRK2 (0.50) | LRRK2OGAMAP3K12CLK2CXCR3 | |
| SCHEMBL20899007 | 0.90 | LRRK2 (0.50) | LRRK2OGAMAP3K12CLK2CXCR3 | |
| SCHEMBL25142006 | 0.90 | LRRK2 (0.50) | LRRK2OGAMAP3K12CLK2CXCR3 | |
| SCHEMBL30477467 | 0.90 | LRRK2 (0.50) | LRRK2OGAMAP3K12CLK2CXCR3 | |
| SCHEMBL30477436 | 0.90 | LRRK2 (0.50) | LRRK2OGAMAP3K12CLK2CXCR3 | |
| SCHEMBL23554883 | 0.83 | LRRK2 (0.45) | LRRK2OGAJAK2TYK2 | |
| SCHEMBL20899483 | 0.83 | LRRK2 (0.45) | LRRK2OGAJAK2TYK2 | |
| SCHEMBL25141914 | 0.83 | LRRK2 (0.45) | LRRK2OGAJAK2TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3694330-B1 | INDAZOLYL-SPIRO[2.2]PENTANE-CARBONITRILE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-04-19 | — | — | EP | disclosed |
| EP-3694330-B1 | INDAZOLYL-SPIRO[2.2]PENTANE-CARBONITRILE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-04-19 | — | — | EP | disclosed |
| EP-3694331-B1 | INDAZOLYL-SPIRO[2.3]HEXANE-CARBONITRILE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2022-11-16 | — | — | EP | disclosed |
| US-11174248-B2 | Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2021-11-16 | — | — | US | disclosed |
| US-11161854-B2 | Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20210188818-A1 | INDAZOLYL-SPIRO[2.3]HEXANE-CARBONITRILE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2021-06-24 | — | — | US | disclosed |
| US-20210188863-A1 | INDAZOLYL-SPIRO[2.2]PENTANE-CARBONITRILE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11161854-B2 | Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | LRRK2, GRK2, CLK2 | LRRK2 1/4885OGA 2564/4885MAP3K12 156/4885 |
| US-11174248-B2 | Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | LRRK2, BRSK2, CLK2 | LRRK2 1/4885OGA 2235/4885MAP3K12 120/4885 |
| US-20210188863-A1 | INDAZOLYL-SPIRO[2.2]PENTANE-CARBONITRILE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | LRRK2, GRK2, CLK2 | LRRK2 1/4885OGA 2564/4885MAP3K12 156/4885 |
| US-20210188818-A1 | INDAZOLYL-SPIRO[2.3]HEXANE-CARBONITRILE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | LRRK2, BRSK2, CLK2 | LRRK2 1/4885OGA 2235/4885MAP3K12 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.